Village Farms International, Inc. Quarterly Report Released - Here’s What You Should Know

Village Farms International, Inc.
Quarter Ended June 30, 2025
Investor Summary

Key Financial Metrics

• Sales for Q2 2025 were $59.9 million, a 12% increase from $53.6 million in Q2 2024. Six-month sales were $99.6 million vs. $95.6 million in the prior period.
• Gross profit for Q2 2025 was $22.3 million (gross margin 37%) up from $13.6 million (gross margin 25%) in Q2 2024. For the six months, gross profit was $36.5 million (37% margin) vs. $24.9 million (26% margin) prior year.
• Net income attributable to shareholders for Q2 2025 was $26.5 million, compared to a loss of $(23.5) million in Q2 2024. For six months, net income was $19.8 million versus a loss of $(26.4) million prior year.
• Adjusted EBITDA for Q2 2025 was $13.3 million, up from $(3.6) million in Q2 2024; for the six months, $13.3 million, up from $32,000.
• Diluted EPS (including discontinued operations) was $0.24 for Q2 2025 versus $(0.21) prior year. For six months: $0.18 vs. $(0.24).
• Cash, cash equivalents, and restricted cash at June 30, 2025: $64.99 million (up from $24.6 million at December 31, 2024).
• Working capital at June 30, 2025: $85.8 million (up from $53.8 million at year-end).
• Total assets: $403.7 million; total liabilities: $109.6 million. Long-term debt was $31.2 million at June 30, 2025 (down from $32.4 million).

Segment Highlights

• Canadian Cannabis:

  • Q2 2025 sales: $44.5 million (up from $40.7M); 57% of sales from branded products; gross profit up 63% year-over-year; adjusted EBITDA up to $11.9 million from $4.8 million.
  • Significant growth in international sales: up 690% YoY, 116% sequential; achieved full-year outlook in six months.
  • Leading dried flower market share sustained; high end of targeted 30-40% gross margin achieved.

• U.S. Cannabis:

  • Q2 2025 sales: $3.8 million (down from $4.3M); adjusted EBITDA $45,000 (versus $(240,000) prior year).
  • Lower sales attributable to regulatory changes and widespread unregulated hemp-derived products.

• Netherlands Cannabis:

  • Q2 2025 sales: $2.5 million (first full quarter post-launch); 66 of 80 coffeeshops now carry products.
  • Gross margin: 58%; net income $835,000; adjusted EBITDA $1.2 million.

• Produce:

  • Q2 2025 sales: $8.6 million (flat); segment reconstituted after divestiture of U.S. produce business.
  • Net income $20.6 million (driven by $19.1 million gain on asset sale).

• Clean Energy:

  • Q2 2025 sales: $483,000.

Discontinued Operations

• Sale of U.S. produce business closed May 30, 2025:
  • Net gain on sale: $19.99 million recognized.
  • Net income from discontinued operations in Q2 2025: $16.3 million (including gain).

Liquidity & Balance Sheet

• Operating cash flow from continuing operations (six months): $22.3 million (vs. $(3.7) million prior year).
• Investing cash outflow: $(5.3) million.
• Financing cash outflow: $(5.0) million (mainly debt payments).
• No share repurchases during quarter.

Risks

• Canadian Cannabis Regulatory and Excise Tax Pressures: Onerous excise taxes continue to impact profitability on branded sales (excise taxes were $14.8 million Q2 2025 and $28.8 million YTD; Management notes "burdensome excise tax").
• Dependence on Key Markets and Regulatory Environments: U.S. segment performance negatively affected by proliferation of unregulated hemp-derived cannabinoid products, especially following July 2024 regulatory changes; delays in Texas medical marijuana license application.
• Execution Risk Post-Divestiture: Company acknowledges risk that expected benefits from privatizing U.S. produce business may not be fully realized (Item 1A Risk Factors).
• High Customer Concentration and Evolving Competitive Landscape: Particularly for cannabis in Canada and produce operations; aggressive competition and regulatory uncertainty cited.
• Debt and Covenant Compliance: As of December 31, 2024, noted previously being out of compliance with certain financial covenants, though restructured and consolidated credit facilities in April 2025. New facility improves rates and extends term.

Management Discussion and Outlook

• The company reports strong momentum in cannabis—Canadian segment achieved targeted profitability and market share objectives, expects continued growth in international medical exports, and forecasts increased capacity and product launches (including anticipation of bringing Netherlands Phase II facility online in early 2026).
• Post-divestiture, focus is on higher-margin, branded, and international cannabis products, energy projects, and greenhouse-grown produce in Canada.
• Management highlights improvement in adjusted EBITDA, gross margins, and cash flow, emphasizing prudent cost control and operational discipline.
• Key capital projects (Netherlands expansion, clean energy partnerships) remain funded and on track; cash runway seen as sufficient for near-term initiatives.
• Company regained Nasdaq listing compliance and appointed a new Corporate Treasurer in the quarter.
• No material legal proceedings disclosed.

Conclusion
Village Farms delivered a strong financial turnaround in Q2 and first-half 2025, with increased margins, net income, and significantly improved cash flow, underpinned by strong Canadian and international cannabis performance and the strategic exit from its U.S. produce business. Investors should monitor regulatory developments (especially in U.S. cannabis/hemp), progress on European expansion, and sustained profitability/margin trends as the company further transitions to a global branded consumer packaged goods focus in cannabis and adjacent categories.

Visit Publicview AI to search and analyze millions of SEC filings using AI.